Radiopharm Theranostics Secures A$35 Million in Fundraising
Radiopharm Theranostics Limited, known for its innovative radiopharmaceutical products, is thrilled to announce a successful capital raise of approximately A$35 million. This amount has been gathered through a private placement, attracting new institutional investors both from Australia and abroad.
Strategic Investment and Share Purchase Plan
In addition to the overall capital raise, Lantheus Holdings has reinforced its commitment as a strategic investor by contributing A$7.6 million, now holding a significant 14.5% stake. This funding is complemented by a planned Share Purchase Plan (SPP) aimed at existing eligible shareholders in Australia and New Zealand, which will seek to raise an additional A$5 million.
Details of the Investment Offers
Under the specific terms of this placement, each participant will receive one free attaching option for every new share purchased. The attaching options, available at an exercise price of A$0.039, will expire on October 31, 2027. This is an encouraging opportunity for investors, enhancing their participation in Radiopharm's growth.
Use of Proceeds from the Capital Raising
The funds generated from both the placement and the SPP will primarily focus on drug manufacturing, support clinical trials, and cover working capital costs. This solid financial footing is expected to extend Radiopharm's operational runway into 2027 while achieving several crucial milestones in its development pipeline.
CEO’s Insights on the Successful Placement
Riccardo Canevari, the Chief Executive Officer and Managing Director of Radiopharm, expressed enthusiasm regarding the closure of this capital raise. He emphasized the financial enhancement this brings to the company and noted that the funds will significantly propel their six ongoing clinical programs towards valuable milestones.
A Closer Look at the Financial Benefits
With the A$35 million placement being executed at a price of A$0.03 per share, it reflects discounts ranging from 11.8% to 18.9% based on previous closing prices. This strategic pricing reinforces the attractiveness of the offering while ensuring that investors find value in their commitments.
Future Growth and Development Strategies
The company aims to utilize around A$19 million of the raised capital to support its administration and corporate costs, indicating a well-rounded approach towards sustainable growth. Radiopharm Theranostics is focusing on scaling its operations and enhancing its product offerings in the dynamic field of radiopharmaceuticals.
Importance of Strategic Partnerships
The ongoing support from Lantheus is pivotal to Radiopharm’s strategy, providing not just financial resources, but also a robust endorsement of the company’s capabilities and technology. This collaboration is indicative of a promising future for Radiopharm, with substantial backing that could lead to further innovation in their product line.
Contact and Additional Information
For more information regarding this capital raise and the company's broader vision, stakeholders are encouraged to connect with:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Paul Hopper
Executive Chairman
E: paulhopper@lifescienceportfolio.com
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Frequently Asked Questions
What is the total amount Radiopharm Theranostics just raised?
The company has successfully raised A$35 million from an institutional private placement.
What is the purpose of the funds raised?
The funds will primarily be used for drug manufacturing, clinical trials, and working capital to extend operational capacity into 2027.
Who is Lantheus and what’s their role in this capital raise?
Lantheus is a strategic investor that contributed A$7.6 million to the placement, highlighting their confidence in Radiopharm's technology and strategy.
Is there an opportunity for existing shareholders to participate in the funding round?
Yes, there is a Share Purchase Plan for eligible shareholders to invest up to A$30,000, raising an additional A$5 million.
What is the exercise price for the attaching options?
The attaching options have an exercise price set at A$0.039, expiring on October 31, 2027.
